Close
Virtual Symposium: Update on AMX0035 CENTAUR and open-label extension trials

Virtual Symposium: Update on AMX0035 CENTAUR and open-label extension trials

Reading Time: 4 minutes This blog is part of the ‘Virtual Highlights’ collection of articles, where you can read about the content of some of the talks and posters presented at the Virtual 31st International Symposium on ALS/MND. This presentation was part of Session 3: Clinical Trials. Presented by Dr Sabrina Paganoni, from the Sean M. Healey & AMG…

Virtual Symposium: Phase 3 clinical trial results – levosimendan

Virtual Symposium: Phase 3 clinical trial results – levosimendan

Reading Time: 2 minutes This blog is part of the ‘Virtual Highlights’ collection of articles, where you can read about the content of some of the talks and posters presented at the Virtual 31st International Symposium on ALS/MND. This presentation was part of Session 3: Clinical Trials. Presented by Dr Merit Cudkowicz, from Harvard Medical School and Massachusetts General Hospital,…

Virtual Symposium: Results from the Phase 3 clinical trial of NurOwn

Virtual Symposium: Results from the Phase 3 clinical trial of NurOwn

Reading Time: 4 minutes This blog is part of the ‘Virtual Highlights’ collection of articles, where you can read about the content of some of the talks and posters presented at the Virtual 31st International Symposium on ALS/MND. This presentation was part of Session 3: Clinical Trials Co-presented by Dr Merit Cudkowicz, from Harvard Medical School and Massachusetts General…

Update on the CENTAUR trial: open label extension data

Update on the CENTAUR trial: open label extension data

Reading Time: 3 minutes A centaur was a creature from Greek mythology which was half-man and half-horse. Despite such an unusual appearance such a combination could have its advantages. It seems that another combination may hold promise in the future for people with ALS/MND (see our previous blog). The CENTAUR clinical trial, which tested a combination of two compounds,…

Targeting Tregs: IMODALS study paves the way for MIROCALS

Targeting Tregs: IMODALS study paves the way for MIROCALS

Reading Time: 4 minutes Although ALS is a neurodegenerative disease, researchers are increasingly also interested in events happening outside the brain and spinal cord, in particular whether changes in the immune system might play a role in influencing the course of the disease. This is a subject we’ve covered before, with particular reference to the ongoing MIROCALS drug trial…

TUDCA-ALS has started recruiting in the UK

TUDCA-ALS has started recruiting in the UK

Reading Time: 3 minutes TUDCA-ALS is a European Consortium (funded by the European Commission under the Horizon 2020 grant) involving top researchers from seven countries across Europe (see Figure 1). The Consortium aims to find a new treatment to slow down the progression of MND/ALS by conducting a clinical trial to investigate the safety and efficacy (effectiveness) of Tauroursodeoxycholic…

New gene therapy targeting C9orf72-ALS begins Phase 1 clinical trial in the UK

New gene therapy targeting C9orf72-ALS begins Phase 1 clinical trial in the UK

Reading Time: 2 minutes This article was written by Dr Keith Mayl and Dr Ahmad Al Khleifat of King’s College London. Researchers at King’s College Hospital, led by Professor Christopher Shaw, have embarked on the first gene therapy clinical trial for patients affected by a specific genetic form of ALS, the most common type of MND. ALS is a…

Could MND be treated by HIV drugs?

Could MND be treated by HIV drugs?

Reading Time: 4 minutes Recently published results from the open-label Lighthouse trial investigating safety of the drug Triumeq in people with MND revealed the treatment was safe and ready to progress to a larger Phase 3 clinical trial. The trial was held in Australia and recruited 40 people with MND who all received the active drug; this was because…